ESSA Pharma (EPIX) Stock Price, News & Analysis

Company Overview

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $1.63 to $1.69
• 50-Day Range: $1.40 to $6.23
• 52-Week Range: $1.40 to $11.67
• Volume: 296,440 shs
• Average Volume: 297,375 shs
• Market Capitalization: $72.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Hold

ESSA Pharma Stock Analysis - MarketRank™

ESSA Pharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 360th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

ESSA Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ESSA Pharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ESSA Pharma are expected to grow in the coming year, from ($0.70) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ESSA Pharma is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ESSA Pharma is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ESSA Pharma has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.56% of the outstanding shares of ESSA Pharma have been sold short.

Short Interest Ratio / Days to Cover

ESSA Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ESSA Pharma has recently decreased by 4.82%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ESSA Pharma does not currently pay a dividend.

Dividend Growth

ESSA Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.56% of the outstanding shares of ESSA Pharma have been sold short.

Short Interest Ratio / Days to Cover

ESSA Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ESSA Pharma has recently decreased by 4.82%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.04

News Sentiment

ESSA Pharma has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for ESSA Pharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,059,947.00 in company stock.

Percentage Held by Insiders

14.70% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EPIX Stock Analysis - Frequently Asked Questions

How have EPIX shares performed this year?

ESSA Pharma's stock was trading at $6.60 at the beginning of the year. Since then, EPIX shares have decreased by 75.2% and is now trading at $1.64.
View the best growth stocks for 2024 here.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) posted its quarterly earnings results on Tuesday, December, 17th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05.

Who are ESSA Pharma's major shareholders?

Top institutional shareholders of ESSA Pharma include Bellevue Group AG (17.76%), RTW Investments LP (7.35%), PFM Health Sciences LP (6.18%) and Parkman Healthcare Partners LLC (0.78%). Insiders that own company stock include David Ross Parkinson, Peter Virsik and Growth N V Biotech.
View institutional ownership trends.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 12/17/2024
• Today: 12/18/2024
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPIX
• CUSIP: N/A
• CIK: 1633932
• Web: www.essapharma.com
• Phone: 778-331-0962
• Fax: 604-738-4080
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.50
• High Stock Price Target: $17.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +479.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-26,580,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.17%
• Return on Assets: -19.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 36.95
• Quick Ratio: 36.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.30 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 44,369,000
• Free Float: 37,847,000
• Market Cap: $72.77 million
• Optionable: Optionable
• Beta: 1.62